Table 4.
Demographic and clinical characteristics of AF patients who underwent electrical cardioversion or pulmonary vein isolation.
| Variable | Electrical cardioversion (n = 27) | Pulmonary vein isolation (n = 48) | p value |
|---|---|---|---|
| Age (years) | 59 (±10) | 57 (±9) | 0.370 |
| Male, n (%) | 20 (74.1) | 34 (70.8) | 0.974 |
| Height (cm) | 175 (±11) | 175 (±10) | 0.885 |
| Weight (kg) | 97.1 (±19.2) | 86.2 (±13.6) | 0.006 |
| Body mass index (kg/m2) | 31.8 (±6.0) | 28.1 (±3.2) | <0.001 |
| Heart rate (beats per minute) | 63 (±10) | 56 (±8) | 0.002 |
| Peripheral systolic blood pressure (pSBP) (mmHg) | 124 (±15) | 128 (±12) | 0.271 |
| Peripheral diastolic blood pressure (pDPB) (mmHg) | 78 (±9) | 79 (±9) | 0.765 |
| Peripheral pulse pressure (pPP) (mmHg) | 46 (±9) | 50 (±9) | 0.154 |
| hsCRP (mg/l) | 2.3 (1.2-4.1) | 1.5 (0.9-3.2) | 0.223 |
| MPO (ng/l) | 84.3 (49.8-131.8) | 40.5 (30.9-72.1) | 0.007 |
| Galectin-3 (mg/l) | 11.4 (10.2-14.8) | 11.1 (9.4-14.4) | 0.613 |
| oxLDL (U/l) | 71.4 (61.9-89.2) | 73.0 (59.6-94.2) | 0.762 |
| NT-proBNP (pg/ml) | 991.0 (365.0-1240.0) | 115.5 (81.0-231.0) | <0.001 |
| Ejection fraction (%) | 53 (±10) | 61 (±7) | <0.001 |
| Left atrial diameter (cm) | 4.1 (±0.5) | 4.0 (±0.5) | 0.656 |
| Left atrial end systolic volume index (ml/m2) | 36.0 (±12.0) | 36.5 (±8.3) | 0.830 |
| CHA2DS2-VASc score, n (SD) | 1.8 (±1.2) | 1.3 (±1.2) | 0.070 |
| AF type Paroxysmal, n (%) Persistent, n (%) |
7 (25.9) 20 (74.1) |
38 (79.2) 10 (20.8) |
<0.001 <0.001 |
| Antiarrhythmic drug None, n (%) Propafenone, n (%) Amiodarone, n (%) Flecainide, n (%) |
5 (18.5) 17 (63.0) 5 (18.5) 0 (0) |
5 (10.4) 27 (56.3) 8 (16.7) 8 (16.7) |
0.524 0.747 0.909 0.064 |
| Use of beta-blockers, n (%) | 22 (81.5) | 45 (93.8) | 0.207 |
| AF recurrence during 1-year follow-up, n (%) | 21 (77.8) | 9 (18.8) | <0.001 |
Values are presented as mean ± SD or median (IQR) or count (%). SD: standard deviation; IQR: interquartile range; hsCRP: high-sensitivity C-reactive protein; MPO: myeloperoxidase; oxLDL: oxidized low-density lipoprotein; NT-proBNP: N-terminal pro-brain natriuretic peptide.